Group 1 - The core point of the article is that Sai Sheng Pharmaceutical (300485.SZ) experienced a significant drop in its stock price, with a decline of 4.11% to 11.66 yuan [2] - The company announced that shareholder Ms. Ma Li will reduce her stake by selling a total of 3.3282 million shares, which represents 0.69% of the company's total share capital [2]

Group 1 - The core point of the article highlights that Sai Sheng Pharmaceutical experienced a stock price increase of 6.39%, closing at 12.16 yuan, with a significant block trade occurring [1] - The block trade involved a total volume of 820,000 shares and a transaction amount of 8.774 million yuan, with the first transaction price at 10.70 yuan, reflecting a premium rate of -12.01% [1] - The buyer was China Galaxy Securities Co., Ltd., and the seller was Industrial Securities Co., Ltd., indicating active trading interest in the stock [1] Group 2 - Over the past three months, the stock has recorded one block trade with a total transaction amount of 8.774 million yuan [1] - In the last five trading days, the stock has seen a cumulative increase of 9.06%, with a net inflow of 20.991 million yuan from major funds [1]

Core Viewpoint - The company, Sai Sheng Pharmaceutical (300485.SZ), has received a notification from Ms. Ma Li regarding her share reduction progress, indicating a planned decrease in her holdings in the company [1] Group 1 - Ms. Ma Li reduced her shareholding by a total of 3.3282 million shares [1] - The reduction represents 0.69% of the company's total share capital [1] - The share reduction occurred between November 18, 2025, and January 13, 2026, through centralized bidding and block trading methods [1]

证券代码：300485 证券简称：赛升药业 公告编号：2026-001 北京赛升药业股份有限公司 关于公司控股股东、实际控制人及一致行动人股份权益 变动触及 1%整数倍的公告 | 1.基本情况 | | | --- | --- | | 信息披露义务人 马丽 | | | 住所 | 北京市海淀区*** | | 2025 年 权益变动时间 | 11 月 18 日-2026 年 1 月 13 日 | | 权益变动过程 | 马丽女士因个人资金需求，于 2025 年 11 月 18 日-2026 年 1 月 | | 13 | 日通过集中竞价和大宗交易方式累计减持公司股份 332.82 | | | | | 司控股股东、实际控制人及一致行动人股份持有公司股份的比 | | | | --- | --- | --- | --- | --- | --- | | | | | 万股，占公司现有总股本比例为 | | 0.69%，本次减持股份后，公 | | | | 例由 57.52%减少至 | 56.83%。权益变动触及 | 1%整数倍。 | | | 股票简称 | 赛升药业 | | 股票代码 | 300485 | | | 变动方向 | 上升□ ...

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical (300485) has reported a total of 33,621 shareholders as of December 31, 2025 [1]

Market Overview - The Shanghai Composite Index closed at 4023.42 points, above the annual line, with a gain of 1.38% [1] - The total trading volume of A-shares reached 30,483.30 billion yuan [1] Stocks Breaking Annual Line - A total of 204 A-shares have surpassed the annual line today, with notable stocks including: - Guanhao Biological (300238) with a deviation rate of 13.10% - Beilu Pharmaceutical (300016) with a deviation rate of 12.97% - Yinkang Life (300143) with a deviation rate of 12.90% [1] Stocks with Significant Deviation Rates - Stocks with high deviation rates include: - Guanhao Biological: 20.00% increase, latest price at 16.62 yuan - Beilu Pharmaceutical: 13.22% increase, latest price at 8.99 yuan - Yinkang Life: 15.18% increase, latest price at 11.38 yuan [1] Additional Stocks with Positive Performance - Other stocks showing positive performance include: - Gangtong Medical (301515) with a 14.16% increase and a deviation rate of 12.82% - Zhite New Materials (300986) with a 20.04% increase and a deviation rate of 10.50% [1] Stocks with Lower Deviation Rates - Stocks that have just crossed the annual line with lower deviation rates include: - Longqi Technology (603341) with a 10.01% increase and a deviation rate of 9.02% - Taihe New Materials (002254) with a 9.98% increase and a deviation rate of 8.61% [1]

Group 1 - The Shanghai Composite Index is at 4005.73 points, above the annual line, with an increase of 0.93% [1] - The total trading volume of A-shares today is 1,402.986 billion yuan [1] - A total of 154 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates including Yingkang Life, Gangtong Medical, and Beilu Pharmaceutical at 10.63%, 10.61%, and 9.97% respectively [1] Group 2 - The top three stocks with the highest deviation rates from the annual line are: - Yingkang Life (12.85% increase, 10.63% deviation) - Gangtong Medical (11.91% increase, 10.61% deviation) - Beilu Pharmaceutical (10.20% increase, 9.97% deviation) [1] - Other notable stocks with significant increases include: - Guanhao Biological (14.87% increase, 8.29% deviation) - Baichu Electronics (6.95% increase, 6.79% deviation) [1] - Stocks with smaller deviation rates that have just crossed the annual line include *ST Yedao, Shiyan Institute, and Shanxi Securities [1]

Group 1 - The core point of the article is that Saiseng Pharmaceutical has announced the approval of a financial assistance extension to its subsidiary Junyuan Pharmaceutical by its fifth board of directors' twelfth meeting [2] Group 2 - The financial assistance is aimed at supporting the operations of Junyuan Pharmaceutical [2] - The decision reflects the company's strategy to ensure the stability and growth of its subsidiary [2] - This move may indicate the company's commitment to maintaining its investment in the pharmaceutical sector [2]

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical announced a board meeting to discuss financial support for its subsidiary, Junyuan Pharmaceutical, and provided details on its revenue composition for 2024 [1] - Sai Sheng Pharmaceutical's revenue for the year 2024 is primarily derived from the pharmaceutical manufacturing sector, accounting for 99.63% of total revenue, while other businesses contribute only 0.37% [1] - As of the report, Sai Sheng Pharmaceutical has a market capitalization of 5.2 billion yuan [1] Group 2 - The article also highlights a significant event involving Moutai's distributor conference, where over 2,000 attendees gathered to discuss major changes related to Moutai's pricing and distribution strategies [1] - Chairman Chen Hua emphasized that distributors can no longer rely on passive income, indicating a shift in the business model [1]

证券代码：300485 证券简称：赛升药业 公告编号：2025-053 北京赛升药业股份有限公司 关于向子公司君元药业提供财务资助展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、北京赛升药业股份有限公司（以下简称"公司"）拟对子公司沈阳君元 药业有限公司（以下简称"子公司"或"君元药业"）提供的财务资助进行展期， 借款期限延长至 2028 年 12 月 28 日，按年利率 3%结算利息。 本次财务资助展期事项不影响公司正常业务开展及资金使用，不属于深交所 《创业板股票上市规则》《创业板规范运作指引》等规定的不得提供财务资助的 情形。 （二）审议情况 本次财务资助展期事项已经公司第五届董事会独立董事专门会议 2025 年第 四次会议、第五届董事会第十二次会议审议通过，无需提交股东会审议。 二、被资助对象的基本情况 （一）基本情况 2、本次财务资助展期事项已经公司第五届董事会独立董事专门会议 2025 年第四次会议、第五届董事会第十二次会议审议通过，无需提交公司股东会审议。 3、本次财务资助展期对象为公司合并报表范围内的子公司，公司 ...